Tags

Type your tag names separated by a space and hit enter

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
Antimicrob Agents Chemother. 2016 07; 60(7):4387-90.AA

Abstract

Ceftolozane-tazobactam is active against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa In a subgroup analysis of patients with complicated intra-abdominal infections (cIAIs) involving P. aeruginosa from a phase 3 program, ceftolozane-tazobactam demonstrated potent in vitro activity against P. aeruginosa Clinical cure in the microbiologically evaluable population was 100% (26/26) for ceftolozane-tazobactam plus metronidazole and 93.1% (27/29) for meropenem. These findings support the use of ceftolozane-tazobactam in the management of cIAI when P. aeruginosa is suspected or confirmed. (This study has been registered at ClinicalTrials.gov under registration no. NCT01445665 and NCT01445678.).

Authors+Show Affiliations

Department of Medical Affairs, Merck & Co., Inc., Kenilworth, New Jersey, USA.Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA myra.popejoy@merck.com.Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA.Department of Surgery, University of Chicago Medical Center, Chicago, Illinois, USA.

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27139477

Citation

Miller, Benjamin, et al. "Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas Aeruginosa From a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study." Antimicrobial Agents and Chemotherapy, vol. 60, no. 7, 2016, pp. 4387-90.
Miller B, Popejoy MW, Hershberger E, et al. Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study. Antimicrob Agents Chemother. 2016;60(7):4387-90.
Miller, B., Popejoy, M. W., Hershberger, E., Steenbergen, J. N., & Alverdy, J. (2016). Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study. Antimicrobial Agents and Chemotherapy, 60(7), 4387-90. https://doi.org/10.1128/AAC.03074-15
Miller B, et al. Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas Aeruginosa From a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study. Antimicrob Agents Chemother. 2016;60(7):4387-90. PubMed PMID: 27139477.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study. AU - Miller,Benjamin, AU - Popejoy,Myra W, AU - Hershberger,Ellie, AU - Steenbergen,Judith N, AU - Alverdy,John, Y1 - 2016/06/20/ PY - 2016/01/14/received PY - 2016/04/25/accepted PY - 2016/5/4/entrez PY - 2016/5/4/pubmed PY - 2017/9/16/medline SP - 4387 EP - 90 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 60 IS - 7 N2 - Ceftolozane-tazobactam is active against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa In a subgroup analysis of patients with complicated intra-abdominal infections (cIAIs) involving P. aeruginosa from a phase 3 program, ceftolozane-tazobactam demonstrated potent in vitro activity against P. aeruginosa Clinical cure in the microbiologically evaluable population was 100% (26/26) for ceftolozane-tazobactam plus metronidazole and 93.1% (27/29) for meropenem. These findings support the use of ceftolozane-tazobactam in the management of cIAI when P. aeruginosa is suspected or confirmed. (This study has been registered at ClinicalTrials.gov under registration no. NCT01445665 and NCT01445678.). SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/27139477/Characteristics_and_Outcomes_of_Complicated_Intra_abdominal_Infections_Involving_Pseudomonas_aeruginosa_from_a_Randomized_Double_Blind_Phase_3_Ceftolozane_Tazobactam_Study_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=27139477 DB - PRIME DP - Unbound Medicine ER -